Werewolf Therapeutics SEC filings document material events, operating results, governance matters, and capital-structure disclosures for a Delaware biopharmaceutical company developing conditionally activated immune therapeutics. Recent 8-K filings furnish quarterly financial results, press-release exhibits, and updates tied to the company’s PREDATOR, INDUKINE, and INDUCER programs.
The filings also cover Nasdaq continued-listing matters, audit committee composition, exit and disposal activities, emerging growth company status, common stock registered under the HOWL symbol, shareholder voting matters, clinical and regulatory disclosures, and risk language related to strategy, operations, development plans, and corporate alternatives.
Werewolf Therapeutics, Inc. received an Amendment No. 5 to a Schedule 13D from a group of investment funds and individuals associated with MPM and UBS Oncology updating their ownership in the company’s common stock. The filing lists multiple reporting persons, including MPM BioVentures 2014, L.P., UBS Oncology Impact Fund L.P., MPM BioImpact LLC and individuals Ansbert Gadicke, Luke Evnin and Todd Foley.
Ansbert Gadicke is reported as beneficially owning 3,368,670 shares, or 6.9% of the common stock, while Luke Evnin and Todd Foley are reported at 4.4% and 3.3%, respectively. The filing states that these percentages are based on 48,540,200 shares of common stock outstanding as of October 29, 2025. Various MPM-managed funds hold additional stakes through complex general partner and managing member relationships.
The reporting persons also disclose a series of open‑market sales of Werewolf common stock since the prior amendment, from December 30, 2025 through January 16, 2026. On each trading day in this period, affiliated funds such as BV 2014, BV 2014(B), AM BV2014 LLC, MPM Oncology Innovations Fund, MPM Asset Management LLC and UBS Oncology sold blocks of shares at average prices generally between about $0.54 and $0.65 per share.
Werewolf Therapeutics director Luke Evnin, through affiliated investment entities, reported indirect sales of common stock of Werewolf Therapeutics, Inc. over three trading days in January 2026. The transactions were executed under a pre-established Rule 10b5-1 trading plan dated September 24, 2025.
On January 13, 2026, affiliated entities sold 43,198 shares at a weighted average price of $0.55, leaving 2,266,671 shares indirectly beneficially owned. On January 14, 2026, they sold 30,616 shares at a weighted average price of $0.57, leaving 2,236,055 shares indirectly beneficially owned. On January 15, 2026, they sold 37,413 shares at a weighted average price of $0.55, leaving 2,198,642 shares indirectly beneficially owned.
The shares were held and sold by entities including MPM Asset Management LLC, MPM BioVentures 2014, L.P., MPM BioVentures 2014(B), L.P., MPM Asset Management Investors BV2014 LLC, and MPM Oncology Innovations Fund, L.P. Evnin is associated with these entities and disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Werewolf Therapeutics director Luke Evnin reported indirect sales of the company’s common stock by affiliated investment entities, executed under a Rule 10b5-1 trading plan dated September 24, 2025. On January 8, 2026, these entities sold 7,716 shares at a weighted-average price of $0.63, on January 9 they sold 24,678 shares at a weighted-average price of $0.61, and on January 12 they sold 58,980 shares at a weighted-average price of $0.57, each across multiple trades within stated price ranges.
After these transactions, the affiliated entities collectively held 2,309,869 shares of Werewolf Therapeutics common stock indirectly. The shares are spread across several MPM-managed entities, and Evnin disclaims beneficial ownership of the securities except to the extent of his pecuniary interest.
Werewolf Therapeutics director Luke Evnin, through affiliated investment entities, reported automatic sales of the company’s common stock under a Rule 10b5-1 trading plan dated September 24, 2025. On January 5, 2026, entities including MPM Asset Management LLC, MPM BioVentures 2014 funds, AM BV2014 and MPM Oncology Innovations Fund sold a total of 18,378 shares at a weighted average price of $0.64, leaving 2,453,919 shares indirectly held. On January 6, they sold 40,761 shares at a weighted average price of $0.65, with 2,413,158 shares indirectly held afterward. On January 7, they sold 11,915 shares at a weighted average price of $0.64, leaving 2,401,243 shares indirectly held. Evnin disclaims beneficial ownership of these securities except to the extent of his pecuniary interest.
Howl received a Rule 144 notice for a planned sale of 6,840 shares of its common stock through Merrill Lynch in San Francisco. The shares have an aggregate market value of $4,407.70 based on the filer’s disclosure and are listed as trading on NASDAQ. The issuer had 48,540,200 common shares outstanding at the time referenced. The seller originally acquired the 6,840 shares in a private placement from the issuer on 05/04/2021, paid in cash on the same date.
A holder of HOWL common stock has filed a Rule 144 notice to sell 13,256 shares of common stock through Merrill Lynch on the NASDAQ, with an aggregate market value of $8,542.17, around January 6, 2026.
The issuer had 48,540,200 shares outstanding at the time referenced. The shares to be sold were originally acquired from the issuer in a private placement on May 4, 2021, for cash.
An existing holder of HOWL common stock has filed a notice of proposed sale under Rule 144, indicating an intention to sell 198,739 common shares through Merrill Lynch on or around 01/06/2026 on the NASDAQ market. The filing lists an aggregate market value of about $128,067.41 for these shares and notes that 48,540,200 common shares were outstanding. The seller originally acquired the 198,739 shares in a private placement from the issuer on 05/04/2021, paid in cash.
Werewolf Therapeutics reported new data from its INDUKINE™ pipeline and outlined priorities for 2026. For WTX-124, Phase 1/1b data as of October 2025 showed objective, durable responses as a monotherapy in several solid tumors and in combination with pembrolizumab. In heavily pretreated advanced cutaneous melanoma, monotherapy delivered a 21% objective response rate, rising to 30% in patients who had previously responded to immunotherapy, with no vascular leak syndrome and limited high-grade side effects. The FDA accepted 18 mg as the recommended dose and provided initial guidance for a monotherapy registration path in relapsed or refractory melanoma after immune checkpoint inhibitors.
For WTX-330, Phase 1b/2 data in the first twelve patients showed favorable tolerability and antitumor activity using an optimized manufacturing process that improved safety, pharmacokinetics, and therapeutic index. At 0.024 mg/kg IV twice weekly, WTX-330 reached a 17-fold higher Cmax than published rhIL-12 with only 0.12% free IL-12, and there was a confirmed partial response in metastatic gall bladder cancer with a 45% tumor reduction. Werewolf plans additional WTX-124 and WTX-330 data in the first half of 2026, is seeking strategic partnerships, and notes that further development and planned INDs for INDUCER T-cell engager candidates WTX-1011 and WTX-2022 will require additional funding.
Werewolf Therapeutics director Luke Evnin reported selling shares of the company’s common stock in three transactions carried out under a Rule 10b5-1 trading plan dated September 24, 2025. On December 15, 2025, affiliated investment entities sold a total of 23,640 shares at a weighted average price of $1.07. On December 16, 2025, they sold 14,548 shares at a weighted average price of $1.05, and on December 17, 2025, they sold 9,983 shares at a weighted average price of $1.14. Following these sales, Evnin reported 2,841,957 shares of Werewolf Therapeutics common stock beneficially owned indirectly through several MPM-managed entities.
Werewolf Therapeutics director Luke Evnin reported insider sales of the company’s common stock in mid-December 2025. On December 10, he reported selling 37,104 shares at a weighted average price of $1.06 per share through MPM-affiliated investment entities. On December 11 and 12, he reported additional sales of 28,009 and 17,858 shares at weighted average prices of $1.07 and $1.08, respectively, each executed in multiple trades within disclosed price ranges. These transactions were carried out under a Rule 10b5-1 trading plan dated September 24, 2025, and after the reported sales he indicated indirect beneficial ownership of 2,890,128 shares held across several MPM-managed funds.